Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-T cell therapy
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-T cell therapy is a class of autologous chimeric antigen receptor (CAR) T-cell therapies designed to target B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. The process involves collecting a patient's T cells, genetically engineering them to express a CAR that recognizes BCMA, expanding them ex vivo, and re-infusing them into the patient. Once infused, these engineered T cells identify and eliminate BCMA-expressing cancer cells. This modality has revolutionized the treatment landscape for relapsed or refractory multiple myeloma, with two FDA-approved products: idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti). Numerous other candidates are currently in clinical development for multiple myeloma and other B-cell malignancies.
- Brand names
- AbecmaCarvykti
- Other names
- anti-BCMA CAR-TBCMA-directed CAR-T cell therapyB-cell maturation antigen chimeric antigen receptor T-cell therapy
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-T cell therapy.